Effects of raloxifene on serum macrophage colony-stimulating factor and interleukin-18 levels in postmenopausal women younger than 60 years

Menopause

Volumn 17, Issue 6, 2010, Pages 1188-1193

  Oztas, Efser ^a   Kurtay, Gulay ^b  

^a UFUK UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Interleukin 18; Macrophage colony stimulating factor; Raloxifene

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 18; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; GROUPS BY AGE; HOT FLUSH; HUMAN; LIPID BLOOD LEVEL; OPEN STUDY; PATHOGENESIS; POSTMENOPAUSE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

C-REACTIVE PROTEIN; CHOLESTEROL; FEMALE; HUMANS; INTERLEUKIN-18; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGE COLONY-STIMULATING FACTOR; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STATISTICS, NONPARAMETRIC;

EID: 78649662606     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181e04a18     Document Type: Article

References (41)

1. Von der Thusen JH, Kuiper J, Van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003;55:133-166.
2. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-581.
3. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008;79: 360-376.
4. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 2008;199:3-11.
5. Gerdes N, Sukhova GK, Libby P, et al. Expression of interleukin-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-257.
6. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104:1598-1603.
7. Seshiah PN, Kereiakes DJ, Vasudevan SS, et al. Activated monocytes induce smooth muscle cell death. Role of macrophage colony-stimulating factor and cell contact. Circulation 2002;105:174-180.
8. Blankeberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
9. Haraguchi K, Kubo M, Saito T, et al. Serum level of macrophage colony-stimulating factor and atherosclerosis in hemodialysis patients. Nephron Clin Pract 2006;102:14-20.
10. Blumenthal RS, Baranowski B, Dowsett SA. Cardiovascular effects of raloxifene: the arterial and venous systems. Am Heart J 2004;147: 783-789.
11. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1451.
12. Saitta A, Morabito N, Frisina N. Cardiovascular effects of raloxifene hydrochloride. Cardiovasc Drug Rev 2001;19:57-74.
13. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003;88:2135-2140.
14. Gianni W, Ricci A, Gazzaniga P, et al. Raloxifene modulates interleukin-6 and tumor necrosis-> synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab 2004;89:6097-6099.
15. H3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial. Arch Gynecol Obstet 2008;277:489-493.
16. Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z. Influence of the selective estrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF->, TGF-A1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur Cytokine Netw 2007; 18:148-153.
17. Yasui T, Uemura H, Hyodo S, et al. Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in post-menopausal women. Atherosclerosis 2009;204:471-475.
18. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor-< and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 2001;88:825-828.
19. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-857.
20. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137. (Pubitemid 44050394)
21. Collins P, Mosca L, Geiger MJ, et al. Effects of selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors. Circulation 2009;119:922-930.
22. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 2003;42:698-704.
23. De Leo W, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 2001;184:350-353.
24. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endo-metrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
25. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-733.
26. Herrington DM, Brosnihan KB, Pusser BE, et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001;86:4216-4222.
27. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214-218.
28. Blum A, Cannon RO. Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and in hypercholesterolemic men. Ann N Y Acad Sci 2001;949:168-174.
29. de Valk-de Roo GW, Stehouwer CD, Meijer P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy post-menopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999;19:2993-3000.
30. Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM. Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 2008;6:928-934.
31. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2000;347: 1557-1565.
32. Welsh P, Woodward M, Rumley A, Lowe G. Associations of plasma pro-inflammatory cytokines, fibrinogen, viscosity and C-reactive protein with cardiovascular risk factors and social deprivation: the fourth Glasgow MONICA study. Br J Haematol 2008;141:852-861.
33. Yasui T, Maegawa M, Tomita J, et al. Changes in serum cytokine concentrations during the menopausal transition. Maturitas 2007;56:396-403. (Pubitemid 46401105)
34. H1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999;103:11-24.
35. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, et al. IL-18 regulates IL-1A-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 2000;97:734-739.
36. Maugeri D, Mamazza C, Lo Giudice F, et al. Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis. Arch Gerontol Geriatr 2005;40:299-305.
37. Ikonomidis I, Andreotti F, Economou E. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100:793-798.
38. Rallidis LS, Zolidaki MG, Manioudaki HS, Laoutaris NP, Velissaridou AH, Papasteriadis EG. Prognostic value of C-reactive protein, fibrinogen, interleukin 6 and macrophage colony stimulating factor in severe unstable angina. Clin Cardiol 2002;25:461-466.
39. Ikonomidis I, Lekakis J, Revela I, Andreotti F, Nihoyannopoulos P. Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J 2005;26: 1618-1624.
40. Kihara T, Miyata Y, Furukawa M, et al. Predictive value of serum macrophage colony-stimulating factor for development of aortic calcification in haemodialysis patients: a 6 year longitudinal study. Nephrol Dial Transplant 2005;20:1647-1652.
41. Devaraj S, Yun JM, Duncan-Staley C, Jialal I. C-reactive protein induces M-CSF release and macrophage proliferation. J Leukoc Biol 2009;85: 262-267.